SARS-CoV-2 - Ruxolitinib - Therapeutic Candidates

SARS-CoV-2 - Ruxolitinib - Therapeutic Candidates


Ruxolitinib, whose commercial name is Jakavi, is a tyrosine kinase inhibitor and more specifically Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) which are JAK-targeting tyrosine kinases.  Ruxolitinib is used for the treatment of certain myeloproliferative syndromes such as myelofibrosis. It is also used for the treatment of Vaquez disease (essential polyglobulia or polycythemia vera or rubra), characterized by polyglobulia and an increase in total blood cell volume.
The Novartis group, which markets Jakavi, began studying the effects of this drug on Covid-19 caused by SARS-CoV-2. The purpose of this clinical study is to determine whether ruxolitinib could mitigate the potential complications of Covid-19 and involves patients with Covid-19-related cytokine shock. This Phase III clinical study is based on the fact that the JAK-STAT pathway is fundamental to many biological processes related to immunity and inflammation, including the mobilization of a cytokine response.

Search result : 352 product found

Refine your search :

RUOCE / IVD
  • Unconjugated 111
  • [3H] 1
  • human 1
  • Biochemicals 206
  • Inhibitor/Antagonist/Agonist 141
  • Inhibitor / Antagonist / Agonist 4
  • Radiochemicals 1
  • human 1
  • Assay 3
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
HY-50856-5mg
 5mg 
NB-42-01315-10mg
 10mg 
NB-42-01315-25mg
 25mg 
NB-42-01316-10mg
 10mg 
NB-42-01316-25mg
 25mg 
HY-50856-1ml
 10mM/1mL 
HY-50856-500mg
 500mg 
10-4511-5mg
 5mg 
SY-INCB018424-5mg
 5 mg 
orb1307364-5mg
 5mg 
orb1307364-200mg
 200mg 
orb1223575-50mg
 50mg 
orb1223575-200mg
 200mg 
orb1307364-50mg
 50mg 
orb1307364-100mg
 100mg 
orb1223575-100mg
 100mg 
orb1223575-10mg
 10mg 
orb1223575-25mg
 25mg 
orb1223575-5mg
 5mg 
orb1307364-25mg
 25mg